Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rein Therapeutics (RNTX) Cash from Operations (2016 - 2025)

Rein Therapeutics filings provide 10 years of Cash from Operations readings, the most recent being 3220000.0 for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Operations rose 33.08% year-over-year to 3220000.0, compared with a TTM value of 19361000.0 through Dec 2025, up 13.14%, and an annual FY2025 reading of 19361000.0, up 13.14% over the prior year.
  • Cash from Operations hit 3220000.0 in Q4 2025 for Rein Therapeutics, up from 3548000.0 in the prior quarter.
  • The five-year high for Cash from Operations was 1640000.0 in Q3 2023, with the low at 10391000.0 in Q4 2023.
  • Median Cash from Operations over the past 5 years was 5478000.0 (2022), compared with a mean of 5503950.0.
  • The sharpest move saw Cash from Operations skyrocketed 76.47% in 2023, then plummeted 169.22% in 2024.
  • Year by year, Cash from Operations stood at 6255000.0 in 2021, then rose by 29.51% to 4409000.0 in 2022, then plummeted by 135.68% to 10391000.0 in 2023, then soared by 53.69% to 4812000.0 in 2024, then soared by 33.08% to 3220000.0 in 2025.
  • According to Business Quant data, Cash from Operations over the past three periods came in at 3220000.0, 3548000.0, and 6418000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.